BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Page 15

Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes)

By Leave a Comment

July 24, 2025, St. Louis, Missouri — Future Medical Products LLC is pleased to announce the launch of PBME Topical (“Pure Bone Marrow Exosomes”). PBME Topical is a cosmetic product in compliance with the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

PBME Topical consists of isolated exosomes from mesenchymal stem cells, the most studied cell in science. These exosomes are composed of phospholipid bilayers with transmembrane proteins and receptors, integrated growth factors, in addition to micro-RNA and messenger-RNA. Exosomes are naturally found in every part of the body, but the source of the exosomes intended for aesthetics, as well as regenerative medicine, is critical. Bone marrow exosomes are considered by some to be the purest form of stem cell therapy without the cell. [Read more…]

uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development

By Leave a Comment

ROCKVILLE, MD, June 16, 2025 – uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks. Developed using uBriGene’s proprietary RNA-LNP reprogramming technology, these iPSC banks are now available to support research, translational development, and clinical applications worldwide. [Read more…]

Vita Therapeutics and I Peace announced a development program to generate iPS- derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells

By Leave a Comment

Palo Alto, CA, July 10, 2025 –  Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.

GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customized in I Peace cGMP facilities. [Read more…]

Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes

By Leave a Comment

  • ‘DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance the development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only recombinant, stable and functional form of Adiponectin
  • First preclinical results confirm remarkable therapeutic potential in treatment of several metabolic diseases, in particular type 2 diabetes and obesity, affecting around two billion patients worldwide
  • Ciloa plans to use funding to implement biomanufacturing of candidate APN-sEV and demonstrate that innovative biotherapy meets all safety criteria to enter clinical phases I and IIa in treatment of obesity and type 2 diabetes

[Read more…]

Cellino’s iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation

By Leave a Comment

AMT Designation Positions Cellino to Accelerate the Development of Scalable, Personalized Regenerative Medicines

CAMBRIDGE, Mass. — Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA’s Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino’s automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0